Psychedelics Investing Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction
Psychedelics Investing Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors
Psychedelics Investing Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives
Psychedelics Investing Nirvana Life Sciences Inc. Announces a Method for Producing MDMA that Reduces Manufacturing Time by Two Thirds
Psychedelics Investing Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs
Psychedelics Investing Nirvana Life Sciences Announces Approval To Build Vancouver Facility From Health Canada
Psychedelics Investing Nirvana Life Sciences announces filing of Patent for novel isolation of 4-PO-Psilocin Prodrug Compound
Psychedelics Investing Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study
Psychedelics Investing Nirvana Life Sciences Announces Partner Symeres Can Produce High Volume Controlled Substances
Walker Lane Resources: Advancing High-grade Gold, Silver assets in North America’s Prolific Regions
Cartier Resources Closes Offering with Paradigm Capital and Concurrent Offering for Aggregate Gross Proceeds of $11,398,596
Juggernaut Increases Oversubscribed Financing to $8,600,000 due to Strong Demand from Institutions and Accredited Investors
